Frova (Frovatriptan Succinate) Patent Expiration, LOE Window & CMS Spending

Frova (Frovatriptan Succinate) by Endo Pharmaceuticals: Off-Patent Genericized (AB Competition), 4 AB generics, $642K 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEndo Pharmaceuticals
FDA Application & PathwayN021006 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$642K
2024 Medicare Part D Spend$382K
2024 Medicaid Spend$260K
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 32.7% 2-yr change)